Félix Blanc-Durand

19PUBLICATIONS
199CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Cancer diagnosisLiquid biopsies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|May 18, 2026
Clinico-molecular predictors of durable response to immune checkpoint inhibitors (ICI) in metastatic cervical cancer (mCC).

|May 05, 2026
Changes in Cyclin E1 expression and CCNE1 amplification in high-grade ovarian carcinomas post-PARP inhibitor exposure.

|Jan 14, 2026
Early Clinical and Molecular Biomarkers in Patients With Advanced Ovarian Cancer Undergoing Neoadjuvant Chemotherapy: CHIVA Phase II GINECO Trial.

Félix Blanc-Durand, Benoit You, Yahia Adnani

|Jan 08, 2026
ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial.

Félix Blanc-Durand, Catherine Genestie, Sergey Nikolaev

|Nov 24, 2025
Predictors of Successful Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Management of Ovarian Cancer.

Claudia Marchetti, Gwenael Ferron, Olivier Colomban

|Jul 24, 2025
Clinical and biological characteristics associated with loss-of-heterozygosity in endometrial cancer.

Felix Blanc-Durand, Etienne Rouleau, Patricia Pautier

Pageof 4

Frequent Collaborators

7 joint publications

Alexandra Leary

4 joint publications

Patricia Pautier

4 joint publications

Isabelle Ray-Coquard

3 joint publications

Florence Joly